2025 Market SizeUSD 15.9 BnBase year
2026 EstimateUSD 17.89 BnEstimated year
2034 ForecastUSD 45.11 BnForecast value
CAGR12.3%2026–2034
Largest RegionNorth America2025
Cell Therapy and Acellular Therapy Market Overview
The global cell therapy and acellular therapy market reached USD 15.9 billion in 2025 and is estimated at USD 17.89 billion in 2026. Revenue is projected to increase to USD 45.11 billion by 2034, equivalent to a 12.3% CAGR over 2026–2034.
47,204Hematopoietic cell transplants in the 2024 EBMT activity surveyEBMT 2024 activity report
6,082CAR-T recipients in the 2024 European activity surveyEBMT activity report
USD 239.5MVericel MACI revenue reported for 2025Vericel FY2025
USD 563MOrganogenesis net product revenue for 2025Organogenesis FY2025
The market comprises therapeutic products and treatment services based on living human cells, alongside cell-free regenerative products such as decellularized extracellular-matrix scaffolds, tissue-engineered vascular conduits and investigational cell-derived secretome preparations. Eligible revenue includes licensed product sales, separately billed transplantation procedures, dedicated contract processing, and bona fide clinical-development or licensing income. The model excludes conventional small-molecule medicines, diagnostic assays, general-purpose laboratory equipment and unapproved commercial exosome injections marketed without regulatory authorization.
Cell-based treatments span autologous CAR-T immunotherapy, tumor-infiltrating lymphocytes, gene-edited hematopoietic cells, cultured cartilage and epidermal grafts, donor-derived stromal cells and established hematopoietic transplantation. The European transplant registry recorded 47,204 hematopoietic cell transplants and 6,082 CAR-T recipients in its 2024 activity survey. Those figures measure clinical activity rather than market revenue, but show the hospital capacity required for collection, conditioning, processing, infusion and extended follow-up.
Acellular wound and vascular products have distinct pricing economics from patient-specific living-cell medicines in U.S. hospitals. Humacyte received U.S. approval for Symvess in December 2024, an engineered vessel composed of extracellular-matrix proteins after removal of manufacturing cells. Established tissue-derived wound matrices also generate commercial sales: Organogenesis reported USD 563.0 million in 2025 net product revenue, while MiMedx recorded USD 419 million. These company totals are broader than the exact modeled acellular subset and are used to describe supplier activity, not summed into the global estimate.
FDA and EMA regulatory distinctions govern commercial access for each cell-derived treatment category. The FDA approved Mesoblast’s Ryoncil for pediatric steroid-refractory acute graft-versus-host disease in December 2024 and approved Abeona’s autologous cell-sheet gene therapy Zevaskyn in April 2025. Conversely, FDA consumer warnings state that exosome products promoted for disease treatment have not received U.S. approval. Europe withdrew Alofisel authorization in December 2024 after confirmatory efficacy was not established, emphasizing that commercial expansion depends on sustained clinical benefit and manufacturing controls.
Source: EBMT activity survey; FDA Ryoncil; FDA Symvess; Organogenesis 2025 results.
Key Takeaways: Cell Therapy and Acellular Therapy Market
- Base-year size: The combined global market generated USD 15.9 billion in 2025 across in-scope therapeutic products, eligible procedures and specialized services.
- Forecast and growth: Revenue is projected to reach USD 45.11 billion in 2034, with a 12.3% CAGR from the 2026 estimate.
- Largest therapy format: Live-cell therapies represented an estimated ~62% of 2025 revenue, led by transplant procedures and licensed cellular medicines.
- Largest clinical application: Oncology represented an estimated ~39% of 2025 revenue, supported by CAR-T and tumor-infiltrating lymphocyte treatment.
- Largest geography: North America represented an estimated ~44% of 2025 revenue, reflecting specialized treatment-center capacity and higher realized prices.
- Growth drivers: New cellular indications, tissue-engineered wound products, broader treatment-center networks, manufacturing automation and improved access support demand.
- Competitive structure: Gilead/Kite, Bristol Myers Squibb, Johnson & Johnson, Mesoblast, Vericel, Organogenesis, MiMedx and Humacyte compete across distinct modalities.
- Coverage: The 2026–2034 outlook evaluates therapy format, clinical application, manufacturing origin and purchasing setting across five regions.
Report Scope & Market Segmentation
This global study measures monetized regenerative treatments using living cells or cell-derived therapeutic materials, distinguishing product sales from transplant and manufacturing services without counting the same invoice twice.
| Report Attribute | Coverage |
|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Therapeutic Format | Live-Cell Therapies; Acellular Tissue & Matrix Products; Cell-Derived Secretome & Vesicle Programs |
| By Clinical Application | Oncology; Hematologic & Immune Disorders; Wound & Vascular Repair; Orthopedic & Cartilage Repair; Other Indications |
| By Manufacturing Origin | Autologous Patient-Specific; Allogeneic Donor-Derived; Decellularized Tissue & Scaffolds; Cell-Free Biologic Fractions |
| By Purchaser Setting | Transplant & Oncology Centers; Surgical Specialty Hospitals; Outpatient Wound Clinics; Clinical Development Sponsors |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Germany; China; Japan; India; Brazil; Saudi Arabia |
| Key Market Players | Gilead Sciences, Inc. (Kite); Bristol Myers Squibb; Johnson & Johnson (Janssen Biotech); Novartis AG; Vertex Pharmaceuticals Incorporated; Mesoblast Limited; Iovance Biotherapeutics, Inc.; Vericel Corporation; Organogenesis Holdings Inc.; MIMEDX Group, Inc.; Humacyte, Inc.; Abeona Therapeutics Inc.; Autolus Therapeutics plc; Neurotech Pharmaceuticals, Inc. |
Market Definition & Revenue Boundaries
Live-cell revenue covers approved and appropriately billed autologous, allogeneic and gene-modified cellular treatments, transplant-related therapeutic services, specialized cell processing and contract manufacturing. For licensed products, count the manufacturer transaction once; where an independent clinical procedure is separately billed, count only its incremental therapeutic service value. Broad oncology drug sales and unrelated hospital admissions are outside the scope.
Acellular revenue includes commercially supplied decellularized tissues, extracellular-matrix grafts, bioengineered acellular conduits and legitimate trial or licensing income for cell-derived secretome technologies. Investigational extracellular vesicles are not described as approved U.S. treatments. A product originally made using cells is classified as acellular only when the final administered therapy contains no viable therapeutic cells, as in Symvess.
Cell Therapy and Acellular Therapy Market Dynamics
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|
| Earlier-line cellular approvals and wider eligible patient populations | High | +3.80% | High | High | High |
| Expansion of regenerative wound and vascular product procurement | High | +3.10% | High | High | Medium |
| More accredited treatment centers and cell-processing capacity | Medium-High | +2.80% | Medium | High | High |
| Manufacturing automation and donor-derived supply models | Medium | +2.40% | Medium | High | High |
| Improved reimbursement and longer follow-up evidence | Low-Medium | +1.80% | Medium | Medium | High |
| Others (clinical collaborations and specialist surgical adoption) | Low | +1.30% | Low | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|
| Complex individualized production and restricted hospital capacity | High | -1.10% | High | High | Medium |
| Uncertain reimbursement and demanding long-term evidence | Medium-High | -0.90% | High | Medium | Medium |
| Regulatory action against unapproved regenerative products | Medium | -0.50% | Medium | Medium | Low |
| Others (tissue supply variability and post-treatment monitoring) | Low | -0.40% | Medium | Low | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 12.3% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
Broader approved indications raise eligible cellular treatment volume
The FDA expanded Casgevy eligibility to children aged two years and older with qualifying sickle cell disease or transfusion-dependent beta-thalassemia in July 2026. Earlier pediatric access increases the number of patients who may enter specialized collection, conditioning and infusion pathways. In oncology, new CAR-T labels also allow treatment earlier in the disease course, enlarging the addressable cohort beyond heavily pretreated patients. Each new indication creates demand for cell processing, inpatient monitoring and long-term pharmacovigilance, not simply another manufacturer shipment.
Regenerative wound and vascular products create repeatable hospital procurement
Organogenesis recorded USD 531.2 million of advanced-wound-care net product revenue in 2025, and MiMedx reported full-year sales of USD 419 million across wound and surgical products. These figures demonstrate established purchasing channels for tissue-derived regenerative materials, although company portfolios include products beyond the precise market boundary. FDA approval of Humacyte’s acellular Symvess introduced a different use case: urgent limb-salvage vascular reconstruction when an autologous vein is unavailable. Hospital contracts, surgeon training and reimbursement coding determine how quickly approved products become routine inventory.
Specialized manufacturing and center capacity limit near-term throughput
Autologous therapy requires leukapheresis or biopsy, chain-of-identity controls, transport to processing facilities, release testing and coordination with patient conditioning. The EBMT survey documented more than six thousand CAR-T recipients in 2024, but access remains concentrated in experienced hospitals with trained clinical teams. Manufacturing slots can be lost to failed starting material, contamination or an unstable patient before infusion. Donor-derived living-cell products and ready-to-implant acellular matrices reduce some scheduling friction, yet introduce their own comparability, storage and tissue-sourcing requirements.
Evidence and payment scrutiny restrain unvalidated regenerative claims
The EMA withdrew Alofisel marketing authorization in December 2024 after a confirmatory study did not show benefit over placebo for complex perianal fistulas. FDA warnings likewise distinguish legitimate investigational exosome research from unapproved products marketed directly to patients. Payers demand durability, defined patient eligibility and comparative effectiveness before accepting high one-time prices. Cell therapies also require management of cytokine-release syndrome, neurologic toxicities and prolonged follow-up. These clinical and regulatory obligations lengthen commercialization timelines even when early studies report promising responses.
Sources: FDA Casgevy, Symvess and exosome safety notices; EMA Alofisel decision; EBMT survey; Organogenesis and MiMedx annual results.
Market Trends & Growth Opportunities
Living-cell oncology moves beyond single hematologic indications
Gilead reported 2025 Yescarta sales of USD 1.495 billion and Tecartus sales of USD 344 million, demonstrating the size of a mature cellular oncology franchise. Kite secured traditional FDA approval for Tecartus in mantle-cell lymphoma in April 2026, supported by confirmatory evidence. Separately, FDA authorization of Amtagvi established a tumor-infiltrating lymphocyte option for selected advanced melanoma patients. Developers are extending cell therapy into solid tumors, but biopsy logistics, tumor microenvironment and treatment-center readiness differ materially from lymphoma care.
Acellular scaffolds progress from wound care into vascular repair
Symvess received FDA authorization in December 2024 for severe extremity arterial injury when urgent revascularization is required and autologous vein grafting is infeasible. The product is manufactured using human vascular cells that are removed before implantation, leaving extracellular-matrix architecture. Its clinical trial recorded 67% primary patency at 30 days among 54 treated patients. This approval creates a regulated precedent for decellularized engineered structures beyond traditional wound dressings, while adoption remains dependent on surgical expertise and evidence for each separate indication.
Commercial manufacturers pursue standardized, scalable treatment workflows
Vericel reported 2025 MACI sales of USD 239.5 million, supported by expansion of trained orthopedic surgeons and investment in a new production facility. Mesoblast’s donor-derived Ryoncil provides an alternative to fully patient-specific cell processing for pediatric graft-versus-host disease. Hospital customers increasingly evaluate batch consistency, delivery lead times and validated storage as closely as trial efficacy. In autologous therapies, automated closed-system processing can reduce operator interventions, but comparability and release specifications must still satisfy regulators before scale advantages are realized.
Evidence-driven regulation separates approved therapies from exosome marketing
FDA consumer notices state that no exosome products are approved for treatment of human disease in the United States. That position is distinct from approved acellular extracellular-matrix devices and biologics, including Symvess. The EMA withdrawal of Alofisel shows that an initial authorization does not guarantee continued market access if confirmatory outcomes disappoint. Developers are therefore emphasizing controlled potency assays, traceable starting material, prospective comparative studies and post-authorization monitoring. This evidence standard favors suppliers that can finance clinical follow-up and maintain manufacturing records over unlicensed treatment clinics.
Cellular and Acellular Therapeutic Landscape
Treatment categories differ by whether the administered material contains viable cells, by source of starting material and by the degree of patient-specific processing. Oncology cell medicines have established regulatory pathways, whereas acellular wound matrices and engineered conduits are procured primarily by surgical services. Each modality needs its own efficacy, release and safety evidence.
| Modality | Approved or Established Example | Regulatory / Clinical Position | Revenue Boundary |
|---|
| Autologous CAR-T | Yescarta; Tecartus; Breyanzi | Licensed for defined hematologic cancers | Manufacturer medicine plus separately billed care |
| Gene-edited hematopoietic cells | Casgevy | FDA pediatric indication expanded July 2026 | Approved product and eligible treatment services |
| Donor-derived stromal cells | Ryoncil | FDA pediatric graft-versus-host approval | Licensed allogeneic product |
| Cultured tissue grafts | MACI; Zevaskyn | Cartilage repair and RDEB wound indications | Implant or cell-sheet product revenue |
| Acellular engineered tissue | Symvess | FDA vascular-trauma indication | Acellular graft sale |
| Exosome and secretome candidates | Investigational programs | No FDA-approved exosome treatment | Documented trial supply or licensing only |
Clinical service intensity differs between CAR-T infusion, cartilage grafting and emergency vascular repair. CAR-T and gene-edited hematopoietic treatment often require cell collection, conditioning chemotherapy, specialist inpatient care and long observation. Cultured cartilage implantation is scheduled around orthopedic surgery and rehabilitation, whereas a vascular graft must be stocked for urgent trauma cases. Those differences shape hospital contracting, working capital and patient throughput. Counting a manufacturer invoice separately from a legitimate hospital service prevents conflating product sales with the complete episode-of-care cost.
FDA approval of Ryoncil in December 2024 recognized a donor-derived mesenchymal stromal-cell product for pediatric steroid-refractory acute graft-versus-host disease. The approved use is specific; it does not establish efficacy of unrelated stem-cell injections for orthopedic, neurologic or cosmetic conditions. Similarly, the agency’s 2025 authorization of Zevaskyn applies to wounds associated with recessive dystrophic epidermolysis bullosa. These precise indications determine eligible patients, distribution controls and reimbursable treatment settings.
In the cell-free category, decellularized matrices have established clinical uses, but purified extracellular vesicles remain a distinct investigational field. Symvess is a tissue-engineered vessel whose manufacturing cells are removed, whereas marketed amniotic tissue products follow different regulatory pathways and indications. Purchasers increasingly require documented source screening, sterilization or aseptic processing, lot traceability and evidence matched to the proposed surgical use. FDA product-level comparability assessments require documented tissue origin and validated manufacturing characteristics.
Cell Therapy and Acellular Therapy Market Segmentation by Clinical Application
Report SegmentationBy Clinical Application
Clinical application classifies each therapy by the primary condition treated. Cancer indications are separated from transplant-related immune disease, wound or vascular reconstruction, cartilage repair and remaining specialist indications to avoid allocating the same patient or invoice to two categories.
Leading ApplicationOncology
Oncology accounted for an estimated ~39% of 2025 revenue. CAR-T products treat defined hematologic malignancies, while Amtagvi provides a tumor-infiltrating lymphocyte option in selected advanced melanoma. Manufacturer investment is concentrated on earlier treatment lines and solid-tumor development, although response monitoring and adverse-event management remain resource-intensive.
Transplant-Linked DemandHematologic & Immune Disorders
Hematopoietic cell transplantation supports treatment of marrow disorders and severe immune conditions, while Ryoncil addresses steroid-refractory acute graft-versus-host disease in pediatric patients. EBMT transplant activity illustrates the infrastructure and clinical expertise required. This category is distinguished from oncology when the principal treated indication is a nonmalignant blood or immune disorder.
Reconstructive ProceduresWound & Vascular Repair
Tissue-engineered skin and acellular matrices support chronic wounds, severe skin injury and selected vascular trauma. FDA-approved Zevaskyn targets wounds in recessive dystrophic epidermolysis bullosa, while Symvess serves a narrowly defined emergency arterial-repair population. Hospital formulary inclusion and procedural evidence influence procurement more directly than broad drug prescribing trends.
Joint RestorationOrthopedic & Cartilage Repair
MACI uses a patient’s cultured chondrocytes on a collagen membrane for focal cartilage defects. Vericel reported continued MACI sales growth in 2025, alongside a larger trained-surgeon network. Cartilage therapies require suitable lesion selection, rehabilitation and orthopedic referral pathways; unapproved general-purpose stem-cell injections are excluded from this application segment.
Other indications include ophthalmic epithelial restoration and investigational tissue-repair programs with documented clinical-development income. Application allocation follows the treated disease, so surgical care settings and product manufacturing origin remain independent segmentation axes.
Cell Therapy and Acellular Therapy Market Segmentation by Manufacturing Origin
Report SegmentationBy Manufacturing Origin
Manufacturing origin identifies whether the therapeutic material comes from the recipient, another donor, a decellularized structural tissue or an isolated cell-free fraction. Each finished product is assigned once according to its final manufacturing and administration characteristics.
Patient-Specific ProcessingAutologous Patient-Specific
Autologous CAR-T, tumor-infiltrating lymphocyte therapies, cultured chondrocytes and gene-edited hematopoietic cells rely on the recipient’s material. Personalized production requires strict chain-of-identity controls and scheduled manufacturing slots. Casgevy and MACI illustrate distinct medical specialties that share a patient-specific production model but have very different delivery pathways.
Donor-Based Living CellsAllogeneic Donor-Derived
Ryoncil is manufactured from donor-derived bone-marrow stromal cells and supplied for a specific pediatric immune complication. Donor sourcing can support batch production and shorter lead times, but immunologic compatibility, potency and manufacturing consistency must be demonstrated. Conventional allogeneic hematopoietic transplantation is included only to the extent that its therapeutic services fall within the revenue definition.
Cell-Removed StructuresDecellularized Tissue & Scaffolds
Acellular grafts retain structural matrix after cells are removed or do not remain viable in the finished therapeutic product. Symvess exemplifies an engineered vessel made from human extracellular-matrix proteins. Other surgical matrices differ by processing, indication and regulatory classification, requiring buyers to assess evidence for the exact material and procedure.
Isolated Bioactive ComponentsCell-Free Biologic Fractions
Secretome and extracellular-vesicle candidates aim to deliver biologic signals without viable therapeutic cells. Because no FDA-approved exosome therapy exists, this category contains only legitimate clinical research supply, collaborations and licensing activity in the market definition. Claims for unlicensed retail treatment are not treated as verified medical-product sales.
Source classification also determines storage, release testing, traceability and the degree of manufacturing automation. The distinctions remain mutually exclusive even when a company supplies several modalities.
Cell Therapy and Acellular Therapy Market Segmentation by Purchaser Setting
Report SegmentationBy Purchaser Setting
Purchaser setting allocates revenue to the organization responsible for the therapeutic purchase or billable treatment episode, rather than simply where a patient first consults a physician. This approach separates specialized transplant centers from operating-room supply, outpatient wound procurement and formal research sponsors.
Complex Treatment HubsTransplant & Oncology Centers
Accredited hospitals manage CAR-T infusion, hematopoietic transplantation, gene-edited cell therapy and tumor-infiltrating lymphocyte procedures. Their purchasing teams coordinate product release, patient conditioning and toxicity management. EBMT activity data and U.S. cellular therapy labeling show why center capability is a constraint on adoption, especially outside major metropolitan referral networks.
Operating-Room DemandSurgical Specialty Hospitals
Orthopedic, burn, reconstructive and vascular surgeons procure cultured cartilage implants, skin substitutes and acellular engineered vessels. Vericel’s MACI program requires surgeon training, while Symvess is intended for urgent arterial reconstruction in a defined clinical circumstance. Procedural reimbursement and local formulary reviews shape the purchasing cycle.
Longitudinal Wound ManagementOutpatient Wound Clinics
Specialized wound centers purchase eligible acellular tissue and matrix products for patients with difficult-to-heal lesions. Product selection depends on wound type, coverage policies, documented healing outcomes and follow-up visits. MiMedx and Organogenesis supply established regenerative tissue portfolios, but only the in-scope therapeutic share enters the combined market.
Formal Development BuyersClinical Development Sponsors
Biopharmaceutical sponsors, contract manufacturers and licensed research programs purchase investigational cell processing, clinical-grade materials and trial supply. This segment includes documented contracts and milestone income for early cell-free programs, not unauthorized clinic sales. Buyers prioritize GMP readiness, comparability protocols and credible regulatory development plans before scaling orders.
Procurement can shift between hospital and outpatient settings as therapies become easier to administer, but high-risk autologous infusions will remain concentrated in qualified specialist centers through the forecast horizon.
Cell Therapy and Acellular Therapy Market Regional Analysis
Regional differences reflect authorization pathways, transplant-center density, reimbursement for high-cost procedures and access to regulated acellular surgical products. North America has the largest revenue pool, while European registries and Asian manufacturing programs support broadening capacity.
North America
Largest region - ~44% of 2025 global revenueNorth America represented an estimated ~44% of 2025 revenue, supported by approved cellular oncology products, specialist transplantation programs and established wound-care procurement. The United States has licensed products spanning CAR-T, tumor-infiltrating lymphocytes, donor-derived stromal cells, engineered skin and acellular vascular grafts. That variety gives hospitals more opportunities to contract for distinct indications, but it also increases demands on pharmacy committees and payer evidence reviews. In 2025 Vericel reported USD 239.5 million of MACI revenue, while Gilead reported more than USD 1.8 billion in combined Yescarta and Tecartus sales. Neither supplier figure is treated as the total regional market. U.S. FDA safety communications also constrain commercial claims for unapproved exosome injections. Canadian access is influenced by provincial reimbursement and designated transplant-center capacity rather than U.S.-style commercial pricing. Across the region, specialized infusion slots, trained surgeons and long-term follow-up are likely to determine practical treatment throughput more than the number of research-stage candidates.
Priority country signals
United States
Selected market signalThe FDA approved Ryoncil for pediatric steroid-refractory acute graft-versus-host disease in December 2024, Symvess for urgent extremity arterial repair later that month, and Zevaskyn for wounds in recessive dystrophic epidermolysis bullosa in April 2025. These distinct authorizations establish separate clinical supply chains for donor-derived cells, acellular vascular grafts and patient-specific skin sheets. FDA public safety notices separately caution U.S. providers against unapproved exosome treatment claims.
Source: FDA regenerative approvals.
Europe
Established transplant base - Registry-backed treatment capacityEuropean markets combine extensive hematopoietic transplantation experience with nationally negotiated access to advanced therapy medicines. The EBMT 2024 survey documented 47,204 hematopoietic cell transplants across 53 countries and 6,082 CAR-T recipients, providing a concrete view of procedure capacity. Germany, France, Italy, Spain and the United Kingdom host specialist centers that can deliver collection, conditioning and infusion. EMA authorization of Holoclar for limbal stem-cell deficiency provides an established non-oncology example, and its conversion to standard authorization in February 2024 followed submission of additional evidence. Commercial viability in Europe depends on indication-specific reimbursement decisions and sustained efficacy evidence. The EU withdrew Alofisel authorization in December 2024 after confirmatory results failed to demonstrate expected benefit. National health technology assessment, hospital budgeting and outcome-based reimbursement can delay launches even after regulatory clearance. European acellular surgical products also operate under device and biologic frameworks that are not interchangeable with the U.S. system. As the region expands access, sustained effectiveness and center-level implementation will remain central to pricing discussions.
Priority country signals
Germany
Selected market signalGerman transplant centers participate in the EBMT activity registry, which reported more than six thousand European CAR-T recipients in 2024. Reimbursement and hospital treatment capacity remain relevant because cellular medicines require collection, preparation, infusion and extended safety observation. The European regulatory system treats authorized advanced therapy medicines differently from unapproved exosome injections, and products must demonstrate indication-specific clinical benefit. National payer decisions therefore influence the pace of treatment adoption.
Source: EBMT 2024 survey.
Asia-Pacific
Expanding local manufacturing - Cell therapy approvals and domestic programsAsia-Pacific demand spans Japan’s long-established regenerative medicine framework, China’s emerging domestic cell-therapy manufacturers and growing transplant services across South Korea, Australia and India. China granted conditional approval to a locally developed mesenchymal stromal-cell therapy for steroid-refractory acute graft-versus-host disease in early 2025, indicating an expanding regulated market beyond imported CAR-T products. Manufacturing economics vary substantially: domestic cell-processing facilities can lower transport distances, yet potency assays and GMP compliance still constrain supply. Japan’s framework has supported specialist tissue and cell programs, while hospital access remains tied to product authorization and reimbursement. Large patient populations alone do not translate into revenue where qualifying centers, financing or clinical-trial infrastructure are limited. India’s regenerative medicine activity is concentrated in specialist hospitals and research programs, with regulatory scrutiny of unproven commercial offerings. Through 2034, local manufacturing, national clinical guidelines and referral networks will determine whether Asia-Pacific narrows its revenue gap with North America.
Priority country signals
China
Selected market signalThe National Medical Products Administration reported a conditional approval for a domestic mesenchymal stromal-cell injection treating steroid-refractory acute graft-versus-host disease in patients aged 14 and above in January 2025. The authorization marks a regulated clinical product rather than unrestricted approval of stem-cell procedures. Chinese hospitals and manufacturers must still establish consistent processing, qualified patient selection and follow-up for each approved indication. Domestic manufacturing programs in China could reduce reliance on imported cellular products at qualified centers.
Source: NMPA China.
Latin America
Regulated advanced therapy adoption - Brazilian post-approval monitoringLatin America remains a smaller market because high-cost personalized infusions are concentrated in a limited number of specialist institutions. Brazil is the regional center for advanced therapy regulation and clinical development, while Mexico, Argentina and Chile have selected transplantation and cellular oncology programs. In January 2025 Brazil’s Anvisa published monitoring reports for registered advanced therapy products, including CAR-T medicines, reflecting continued attention to benefit-risk assessment after approval. Those reports cover qualified hospitals and long-term safety obligations, rather than authorizing all regenerative services advertised to patients. Public payer budgets and exchange-rate movements affect access to imported cellular products. Acellular wound matrices have broader potential distribution through private surgical and outpatient networks, although evidence and reimbursement must be assessed product by product. Regional expansion will depend on local processing partnerships, specialist training and transparent regulation of tissue-derived therapies. Cross-border patient referrals remain a secondary pathway rather than a substitute for domestic center capacity.
Priority country signals
Brazil
Selected market signalAnvisa released periodic monitoring reports in January 2025 for registered advanced therapies, including Carvykti, Kymriah, Yescarta and other products. The program reviews long-term effectiveness, safety and the qualified hospitals administering treatment. Brazil also supports domestic research collaborations, but experimental CAR-T programs are not interchangeable with licensed routine care. These oversight mechanisms shape adoption, payer confidence and the commercial position of regulated cellular products.
Source: Anvisa monitoring program.
Middle East & Africa
Specialist-center investment - Saudi clinical manufacturing activityMiddle East and Africa account for a smaller share of global regenerative therapy revenue, with advanced cellular treatment concentrated in well-funded specialist centers. Saudi Arabia and the United Arab Emirates have invested in precision oncology and transplant infrastructure, while access in much of sub-Saharan Africa is limited by laboratory capacity, patient financing and the need for intensive supportive care. Saudi regulators authorized a Phase I clinical study of locally developed CAR-T cells in August 2025, a research milestone rather than a product marketing approval. King Faisal Specialist Hospital reported more than 200 patients treated with CAR-T since 2020 and announced local manufacturing activity in October 2025. These initiatives could reduce dependence on overseas processing, but licensed commercialization still requires evidence, quality systems and regulatory review. Acellular wound-care materials may reach a wider hospital network than complex autologous infusions because they can be stocked and implanted by surgical teams. Regional growth will be uneven, led by countries able to fund qualified centers and long-term follow-up.
Priority country signals
Saudi Arabia
Selected market signalThe Saudi Food and Drug Authority approved registration of a Phase I study for locally developed CAR-T cells targeting CD19-positive acute lymphoblastic leukemia on 28 August 2025. The product remains investigational; the authorization permits clinical research rather than routine commercial marketing. The program involves King Faisal Specialist Hospital and a closed transduction system, providing a route to build local manufacturing expertise and specialized treatment capacity.
Source: Saudi Food and Drug Authority.
Regulatory Status, Clinical Evidence & Development Pipeline
Regulatory classification follows the final therapeutic product and claimed indication. Living-cell medicines, tissue-engineered grafts, acellular implants and investigational extracellular vesicles face different review pathways; approval in one category cannot be generalized to another.
| Date | Authority / Event | Product or Program | Market Significance |
|---|
| July 2026 | FDA pediatric indication expansion | Casgevy | Wider eligible age range |
| April 2025 | FDA cell-sheet approval | Zevaskyn | New licensed wound treatment |
| March 2025 | FDA product approval | Encelto | Encapsulated cell-based ocular therapy |
| December 2024 | FDA acellular conduit approval | Symvess | Engineered vascular scaffold precedent |
| December 2024 | FDA donor-derived cell approval | Ryoncil | First U.S. licensed MSC therapy |
| December 2024 | EMA withdrawal | Alofisel | Confirmatory efficacy requirement |
The FDA’s July 2026 Casgevy supplement expanded the labeled population to children aged two and older for qualifying sickle cell disease and transfusion-dependent beta-thalassemia. The product is made from the patient’s edited hematopoietic stem cells and requires myeloablative conditioning. It should not be classified as a free-standing gene-delivery medicine that contains no living therapeutic cells. Separate 2025 approvals for Zevaskyn and Encelto show how cell-based approaches extend beyond blood cancers.
FDA authorization of the acellular Symvess vascular graft established a distinct clinical precedent in 2024. FDA authorization of Symvess covers a specific vascular-trauma indication and describes a vessel made from extracellular-matrix proteins. That authorization does not cover unrelated exosome injections, which FDA safety communications identify as unapproved for disease treatment. Evidence packages must therefore be aligned to each product’s actual composition, manufacturing controls and clinical claim.
European experience demonstrates the importance of confirmatory studies after launch. Alofisel was withdrawn in December 2024 when later evidence did not establish the expected clinical benefit. In contrast, EMA documentation for Holoclar records its progression from conditional to standard authorization after additional information was supplied. Product developers face ongoing obligations for pharmacovigilance, long-term patient outcomes, validated potency assays and consistent manufacturing comparability in each approved indication.
Competitive Landscape
Competition is divided among large oncology drug developers, specialist living-cell manufacturers and suppliers of regenerative surgical materials. No listed manufacturer supplies every authorized oncology, cartilage, wound and vascular indication. Revenue comparisons require care because oncology portfolios, hospital procedures and tissue products follow different reporting conventions, while the market includes only the relevant in-scope portion of each business.
Cellular OncologyGilead/Kite, Bristol Myers Squibb and Johnson & Johnson
Kite markets Yescarta and Tecartus; Bristol Myers Squibb develops Breyanzi and Abecma; Johnson & Johnson markets Carvykti with its partner. Earlier-line CAR-T labels and accredited infusion centers shape manufacturer competition in hematologic oncology.
Patient-Specific RegenerationVertex, Iovance, Vericel and Abeona
Vertex supplies Casgevy; Iovance markets Amtagvi; Vericel commercializes MACI and Epicel; Abeona obtained U.S. authorization for Zevaskyn. These FDA-licensed products require separate biopsy or apheresis pathways and specialized clinical delivery.
Donor-Derived CellsMesoblast and Neurotech Pharmaceuticals
Mesoblast markets Ryoncil for a defined pediatric immune complication, while Neurotech developed the FDA-approved encapsulated cell-based ocular product Encelto. FDA-defined clinical indications and donor-derived batch controls differentiate these cellular businesses.
Acellular Surgical MaterialsOrganogenesis, MiMedx and Humacyte
Organogenesis and MiMedx supply established regenerative tissue portfolios; Humacyte commercializes the acellular engineered vessel Symvess. Hospital procurement contracts for these products focus on wound, reconstructive and vascular procedures.
Gilead’s 2025 financial report disclosed Yescarta revenue of USD 1.495 billion and Tecartus revenue of USD 344 million. The company also reported a decline in fourth-quarter cell-therapy sales because of competition, showing that broader clinical use does not automatically translate into higher revenue for every product. Bristol Myers Squibb obtained additional European Breyanzi approvals during 2025, while Johnson & Johnson reported longer follow-up from Carvykti-treated myeloma patients. Competition increasingly centers on indication breadth, safety monitoring and manufacturing reliability.
In regenerative surgery, Vericel reported USD 276.3 million total 2025 revenue, including USD 239.5 million from MACI. Organogenesis recorded USD 563.0 million in net product revenue, and MiMedx reported USD 419 million in sales. These figures demonstrate supplier scale but cover different product portfolios and must not be added together as a market estimate. Product differentiation rests on published clinical outcomes, surgical training, lot consistency and contracting with hospital systems.
Commercial-stage specialists also compete for scarce capital and manufacturing expertise. Mesoblast’s Ryoncil and Humacyte’s Symvess both obtained FDA authorization in December 2024, but their products treat unrelated clinical needs and cannot substitute for each other. Abeona’s Zevaskyn adds a rare-disease wound therapy, and Autolus markets Aucatzyl for defined B-cell acute lymphoblastic leukemia. Smaller suppliers may partner with contract manufacturers or larger distributors to support validated production and regional access.
Key Companies Profiled
- Gilead Sciences, Inc. (Kite)
- Bristol Myers Squibb
- Johnson & Johnson (Janssen Biotech)
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- Mesoblast Limited
- Iovance Biotherapeutics, Inc.
- Vericel Corporation
- Organogenesis Holdings Inc.
- MIMEDX Group, Inc.
- Humacyte, Inc.
- Abeona Therapeutics Inc.
- Autolus Therapeutics plc
- Neurotech Pharmaceuticals, Inc.
Recent Developments in the Cell Therapy and Acellular Therapy Market
July 2026: The FDA expanded Casgevy eligibility to children aged two years and older with qualifying sickle cell disease or transfusion-dependent beta-thalassemia. The gene-edited autologous hematopoietic cell product previously served patients aged twelve and older. Earlier treatment creates new demand for pediatric transplant infrastructure, conditioning support and long-term monitoring at qualified centers. Source
April 2026: Kite announced FDA traditional approval for Tecartus in relapsed or refractory mantle-cell lymphoma, incorporating confirmatory ZUMA-2 evidence. The decision replaced the earlier accelerated status for that indication and included an expanded treatment population. The update supports earlier referral opportunities while preserving requirements for specialized CAR-T safety management and qualified infusion sites. Source
April 2025: The FDA approved Zevaskyn, Abeona’s autologous cell-sheet gene therapy for wounds associated with recessive dystrophic epidermolysis bullosa. The approval added a patient-specific regenerative product to the U.S. therapeutic portfolio. Its manufacturing pathway links biopsy collection, cell expansion and graft delivery to a rare-disease surgical service network. Source
March 2025: The FDA approved Encelto, Neurotech Pharmaceuticals’ encapsulated cell-based treatment for adults with idiopathic macular telangiectasia type 2. The decision demonstrated an ophthalmic application for living therapeutic cells outside hematology and oncology. Delivery requires specialist ocular procedures and a distinct clinical follow-up pathway from systemic cell infusion. Source
December 2024: The FDA authorized Symvess, Humacyte’s acellular tissue-engineered vessel, for specified extremity arterial trauma when urgent revascularization is needed and an autologous vein graft cannot be used. The decision established a licensed use for a decellularized engineered conduit, with surgeon training and hospital stocking central to adoption. Source
December 2024: The FDA approved Ryoncil, a donor-derived mesenchymal stromal-cell therapy for pediatric steroid-refractory acute graft-versus-host disease. It was the first U.S. FDA-approved mesenchymal stromal-cell therapy. The narrowly defined indication creates a regulated alternative for selected transplant complications without validating unapproved stem-cell procedures promoted for unrelated conditions. Source
Market Outlook, 2026–2034
The market is forecast to increase from USD 17.89 billion in 2026 to USD 45.11 billion by 2034, a 12.3% CAGR. Expansion depends on additional approved indications, sustained efficacy evidence and the ability of hospitals to deliver increasingly complex living-cell treatments alongside scalable acellular surgical products.
| Forecast Variable | 2025–2026 Evidence | Expected 2034 Influence |
|---|
| Cellular oncology | Established CAR-T sales and new indications | More eligible patients and treatment lines |
| Donor-derived therapies | Ryoncil FDA approval | Broader off-the-shelf development |
| Acellular implants | Symvess authorization; wound matrix sales | More specialist surgical procurement |
| Manufacturing capacity | Center throughput and GMP constraints | Automation and network expansion |
| Regulatory oversight | Alofisel withdrawal; FDA exosome warning | Higher evidence threshold for new products |
| Regional access | EBMT registry; Anvisa monitoring | Uneven expansion of qualified centers |
Living-cell oncology will remain a substantial source of revenue because product pricing reflects complex individualized production and the clinical need for intensive monitoring. Yet revenue will not grow uniformly across franchises: Gilead’s 2025 cell-therapy results showed competitive pressure even as new treatment labels emerged. Developers able to reach earlier lines of therapy, reduce production failures and demonstrate durable outcomes should be better positioned than products restricted to late salvage use. Autologous processing will continue to require hospital scheduling and logistics coordination.
Donor-derived stromal cells and other allogeneic platforms offer a different route to expansion. Ryoncil’s approval establishes a defined U.S. pediatric indication, but follow-on conditions require independent clinical evidence. Manufacturers may seek larger batches and more predictable inventory than patient-specific autologous systems permit. Release testing, donor qualification and post-treatment monitoring remain essential, and new indications cannot be assumed from shared cell origin alone. Commercial uptake is therefore expected to follow clinical validation rather than research publication counts.
Acellular tissue products are positioned for growth through wound care, orthopedic reconstruction and vascular surgery, where hospital procurement can be repeated across many procedures. Organogenesis and MiMedx already report meaningful product sales, while Symvess provides a newer engineered conduit for selected arterial injuries. Adoption will depend on coverage decisions, healing outcomes and surgeon familiarity. Investigational extracellular vesicles may contribute licensing and trial supply income, but unapproved retail exosome injections remain outside the legitimate commercial market.
Geographic development will reflect country-specific reimbursement, hospital capacity and regulatory maturity through 2034. North America benefits from established manufacturer networks and specialist hospitals; Europe has deep transplant expertise but faces country-specific health technology assessments. China is developing domestic stromal-cell treatments, Brazil is strengthening post-registration oversight, and Saudi Arabia is building investigational CAR-T manufacturing capability. Through 2034, these developments can widen access if treatment centers, payer budgets and regulatory capacity expand together. Failure to establish durable outcomes or reproducible product quality remains a material downside risk.
Report Coverage
Coverage separates living-cell therapeutic revenue from final acellular products and documents how regulated clinical services contribute to demand without duplicate manufacturer counting.
Market Sizing & Forecasting2025 base, 2026 estimate, 2034 forecast and CAGR reconciliation.
Therapeutic FormatsLive-cell, acellular tissue and legitimate cell-free development income.
Clinical ApplicationsOncology, immune disorders, wound and vascular repair, cartilage and other indications.
Manufacturing & ProcurementAutologous, allogeneic, decellularized and cell-free origins; purchasing settings.
Geographic CoverageFive regions with official country-level regulatory and clinical evidence.
Competition & Regulatory ReviewApproved products, specialist suppliers, dated developments and commercialization risks.
Frequently Asked Questions
What is the global cell therapy and acellular therapy market size?
The global market reached USD 15.9 billion in 2025 and is estimated at USD 17.89 billion in 2026. Revenue is forecast at USD 45.11 billion in 2034. The boundary includes regulated living-cell treatments, qualifying transplant services, acellular therapeutic products and legitimate clinical-development income, without counting an identical transaction twice.
What CAGR is expected for cell and acellular therapies through 2034?
The combined market is projected to grow at a 12.3% compound annual rate from 2026 to 2034. Expansion reflects additional approved cell-therapy indications, improved treatment-center capacity and rising surgical procurement of regenerative tissue products. Manufacturing constraints, payer reviews and indication-specific clinical evidence temper global revenue growth through 2034.
What is the difference between cell therapy and acellular therapy?
Cell therapy administers viable therapeutic cells, such as CAR-T lymphocytes, donor-derived stromal cells or cultured cartilage cells. Acellular therapy uses materials without living therapeutic cells at administration, including decellularized extracellular-matrix grafts and engineered vascular conduits. Cell-derived exosome candidates are a separate investigational category rather than broadly approved clinical treatments.
Which region leads the cell therapy and acellular therapy market?
North America represented an estimated ~44% of 2025 global revenue. The United States has licensed therapies across oncology, immune complications, cartilage, skin and acellular vascular repair, supported by specialist treatment centers. Europe has extensive transplant capacity, while Asia-Pacific is expanding domestic manufacturing and regulated cellular programs.
What is the largest therapeutic format in this market?
Live-cell therapies accounted for an estimated ~62% of 2025 revenue, including transplant-related services and licensed cellular medicines. Autologous CAR-T, cultured chondrocytes, gene-edited hematopoietic cells and donor-derived stromal therapies contribute to this segment. Acellular surgical products form a separate commercial category with different procurement economics.
Are exosome therapies approved by the FDA?
No FDA-approved exosome products for treatment of human disease were identified in the agency’s public safety notices. Research and regulated clinical trials can investigate extracellular vesicles, but commercial injections promoted for unrelated diseases should not be presented as approved medicines. Acellular FDA-approved Symvess is an engineered vascular graft, not an exosome therapy.
Which approved products illustrate living-cell therapy?
Examples include Yescarta and Tecartus for defined blood cancers, Amtagvi for selected advanced melanoma, Casgevy for qualifying blood disorders, Ryoncil for pediatric steroid-refractory graft-versus-host disease and MACI for cartilage repair. Each product has a specific authorized population, manufacturing pathway and clinical setting; approval does not extend to other indications.
What is an FDA-approved acellular regenerative product?
Symvess is an FDA-approved acellular tissue-engineered vessel used for specified extremity arterial injuries when urgent revascularization is necessary and a suitable autologous vein is unavailable. Its final structure contains extracellular-matrix proteins rather than living therapeutic cells. Other FDA-regulated tissue-derived surgical products carry separate indications and manufacturing classifications.
Who are the main companies in cell and acellular therapies?
Participants include Gilead/Kite, Bristol Myers Squibb, Johnson & Johnson, Novartis, Vertex, Mesoblast, Iovance, Vericel, Organogenesis, MiMedx, Humacyte, Abeona, Autolus and Neurotech Pharmaceuticals. Their products span different clinical and regulatory categories, so broad company revenues are not directly interchangeable as measures of this combined market.
Why are cell therapies expensive to manufacture and deliver?
Patient-specific treatments require collection, identity-controlled processing, specialized quality testing, transport, hospital conditioning and monitoring for serious adverse effects. Production can fail when starting material is unsuitable or release criteria are not met. Qualified treatment-center capacity and reimbursement for the complete care episode also constrain access.
What changed in cellular therapy regulation during 2024–2026?
The FDA approved Ryoncil and Symvess in December 2024, Zevaskyn and Encelto in 2025, and expanded Casgevy pediatric eligibility in July 2026. Europe withdrew Alofisel authorization in December 2024 after confirmatory efficacy concerns. These decisions show both widening clinical options and continuing evidence requirements.
How will the market develop through 2034?
Growth is expected from broader licensed indications, improved cell-processing throughput, additional specialist treatment sites and wider use of acellular reconstructive products. Clinical validation will remain decisive, especially for donor-derived cells and investigational vesicles. North America should retain value leadership while Asian and other regional programs gradually expand local manufacturing and access.
Research Sources & Evidence Base
View research sources used for this overview
- FDA. Ryoncil approval for pediatric steroid-refractory aGVHD, December 2024.
- FDA. Symvess first acellular tissue-engineered vessel approval, December 2024.
- FDA. Casgevy approval expansion to young children, July 2026.
- FDA. Zevaskyn approved cell-sheet gene therapy, April 2025.
- FDA. Encelto cell-based ocular therapy authorization, March 2025.
- FDA. Amtagvi tumor-infiltrating lymphocyte approval, February 2024.
- FDA. Public safety notification on unapproved exosome products, December 2019.
- FDA. CBER RMAT approval list including Symvess and Zevaskyn, September 2025.
- EMA. Holoclar stem cell therapy authorization history, April 2026.
- EMA. Alofisel authorization withdrawal and evidence assessment, December 2024.
- EBMT / PubMed. 2024 European hematopoietic transplantation and CAR-T activity, June 2026.
- Vericel Corporation. Second-quarter 2026 financial results and MACI guidance, August 2026.
- Organogenesis. Fourth-quarter and full-year 2025 product revenue, February 2026.
- MiMedx. Full-year 2025 wound and surgical product sales, February 2026.
- Humacyte. Third-quarter 2025 Symvess launch and revenue, November 2025.
- Gilead Sciences. 2025 Yescarta and Tecartus financial results, February 2026.
- Kite / Gilead. Tecartus traditional FDA approval for mantle-cell lymphoma, April 2026.
- Bristol Myers Squibb. European Commission Breyanzi follicular lymphoma approval, March 2025.
- Johnson & Johnson. Carvykti long-term myeloma follow-up, December 2025.
- China NMPA. First domestic mesenchymal stromal cell therapy conditional approval, January 2025.
- Anvisa Brazil. Post-registration monitoring of advanced therapies, January 2025.
- Saudi Food and Drug Authority. Phase I trial registration for locally developed CAR-T, August 2025.
- FDA. Aucatzyl and Tecelra listed in RMAT approvals, December 2024.
- FDA. Carvykti current indications and safety labeling, October 2025.